Toxicity to sensory neurons and Schwann cells in experimental linezolid-induced peripheral neuropathy

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 3, 2016, Pages 685-691

  Bobylev, Ilja ^a,b   Maru, Helina ^a,b   Joshi, Abhijeet R ^a,b   Lehmann, Helmar C ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL VIABILITY; CONTROLLED STUDY; DRUG MEGADOSE; IN VITRO STUDY; LONG TERM CARE; LOW DRUG DOSE; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NERVE CONDUCTION; NERVE FIBER GROWTH; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; RAT; SCHWANN CELL; SCHWANN CELL CULTURE; SCIATIC NERVE; SENSORY NERVE CELL; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; MITOCHONDRION; PATHOLOGY; PHYSIOLOGY; SKIN;

ANIMALS; ANTI-BACTERIAL AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; LINEZOLID; MALE; MICE, INBRED C57BL; MITOCHONDRIA; PERIPHERAL NERVOUS SYSTEM DISEASES; SCHWANN CELLS; SCIATIC NERVE; SENSORY RECEPTOR CELLS; SKIN;

EID: 84960824702     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv386     Document Type: Article

References (31)

1. Chiappini E, Conti C, Galli L et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther 2010; 32: 66-88.
2. Manji H. Drug-induced neuropathies. Handb Clin Neurol 2013; 115: 729-42.
3. Anger HA, Dworkin F, Sharma S et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010; 65: 775-83.
4. Koh W-J, Kang YR, Jeon K et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 2012; 67: 1503-7.
5. Schecter GF, Scott C, True L et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
6. Sotgiu G, Centis R, D'Ambrosio L et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-42.
7. Beekmann SE, Gilbert DN, Polgreen PM et al. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis 2008; 62: 407-10.
8. Chao C-C, Sun H-Y, Chang Y-C et al. Painful neuropathy with skin denervation after prolonged use of linezolid. BMJ Case Rep 2009; 2009: bcr08.2008.0702.
9. Ferry T, Ponceau B, Simon M et al. Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection 2005; 33: 151-4.
10. Heckmann JG, Dütsch M, Schwab S. Linezolid-associated small-fiber neuropathy. J Peripher Nerv Syst 2008; 13: 157-8.
11. Kulkarni K, Del Priore LV. Linezolid induced toxic optic neuropathy. Br J Ophthalmol 2005; 89: 1664-5.
12. Linam WM, Wesselkamper K, Gerber MA. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr Infect Dis J 2009; 28: 149-51.
13. Rucker JC, Hamilton SR, Bardenstein D et al. Linezolid-associated toxic optic neuropathy. Neurology 2006; 66: 595-8.
14. De Vriese AS, Coster RV, Smet J et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42: 1111-7.
15. Bobylev I, Joshi AR, Barham M et al. Paclitaxel inhibits mRNA transport in axons. Neurobiol Dis 2015; 82: 321-31.
16. Leandri M, Ghignotti M, Emionite L et al. Electrophysiological features of the mouse tail nerves and their changes in chemotherapy induced peripheral neuropathy (CIPN). J Neurosci Methods 2012; 209: 403-9.
17. Ko M-H, Chen W-P, Hsieh S-T. Neuropathology of skin denervation in acrylamide-induced neuropathy. Neurobiol Dis 2002; 11: 155-65.
18. Kaewkhaw R, Scutt AM, Haycock JW. Integrated culture and purification of rat Schwann cells from freshly isolated adult tissue. Nat Protoc 2012; 7: 1996-2004.
19. Bei F, Smith KJ. Axonal protection achieved by blockade of sodium/calcium exchange in a new model of ischemia in vivo. Neuropharmacology 2012; 63: 405-14.
20. Miyazaki S, Fujikawa T, Kobayashi I et al. The in vitro and in vivo antibacterial characterization of vancomycin and linezolid against vancomycin-susceptible and-resistant enterococci. J Antimicrob Chemother 2002; 50: 971-4.
21. Pultz NJ, Stiefel U, Donskey CJ. Effects of daptomycin, linezolid, and vancomycin on establishment of intestinal colonization with vancomycinresistant enterococci and extended-spectrum-β-lactamase-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother 2005; 49: 3513-6.
22. Zivkovic SA, Lacomis D. Severe sensory neuropathy associated with long-term linezolid use. Neurology 2005; 64: 926-7.
23. Ciutat D, Calderó J, OppenheimRWet al. Schwann cell apoptosis during normal development and after axonal degeneration induced by neurotoxins in the chick embryo. J Neurosci 1996; 16: 3979-90.
24. Kirischuk S, Parpura V, Verkhratsky A. Sodium dynamics: another key to astroglial excitability? Trends Neurosci 2012; 35: 497-506.
25. Michel LYM, Hoenderop JGJ, Bindels RJM. Towards understanding the role of the Na+-Ca2+ exchanger isoform 3. Rev Physiol Biochem Pharmacol 2015; 168: 31-57.
26. Kerschensteiner M, Schwab ME, Lichtman JW et al. In vivo imaging of axonal degeneration and regeneration in the injured spinal cord. Nat Med 2005; 11: 572-7.
27. Knöferle J, Koch JC, Ostendorf T et al. Mechanisms of acute axonal degeneration in the optic nerve in vivo. Proc Natl Acad Sci USA 2010; 107: 6064-9.
28. Wang JT, Medress ZA, Barres BA. Axon degeneration: molecular mechanisms of a self-destruction pathway. J Cell Biol 2012; 196: 7-18.
29. Brown GC, Borutaite V. Nitric oxide, mitochondria, and cell death. IUBMB Life 2001; 52: 189-95.
30. Bernstein BW, Bamburg JR. Actin-ATP hydrolysis is a major energy drain for neurons. J Neurosci 2003; 23: 1-6.
31. Su KG, Banker G, Bourdette D et al. Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep 2009; 9: 411-7.